US appeals court again invalidates Teva MS drug patent

NEW YORK - A US appeals court on Thursday once again invalidated a patent held by Teva Pharmaceutical Industries Ltd on its top-selling multiple sclerosis drug Copaxone, clearing the way for the launch of a cheaper, generic version.
The decision is the second time the US Court of Appeals for the Federal Circuit has reviewed the Teva patent and comes after the US Supreme Court in January asked it to reconsider a previous decision to cancel the patent.
Subscribe for our daily newsletter
Subscribe for our daily newsletter

By subscribing I accept the terms of use and privacy policy